Preserving Lentiviral Titer During Sterile Filtration Using Recombinant Albumin

EXECUTIVE SUMMARY Lentivirus production is central to CAR-T manufacturing, and is even more critical with the emergence of in vivo CAR-T approaches. This puts increased emphasis on the need for high-yield lentivirus manufacturing. However, lentiviruses are inherently fragile, and infectious titer is lost at every step in manufacturing.  The shift towards suspension systems, and chemically …

Beyond Synthetic Surfactants: The Case for Recombinant Human Serum Albumin (rHSA) as an Ideal Alternative to Poloxamer 188

Reading time: 4 minutes Share this article: For decades, the biopharmaceutical industry has relied on Pluronic F68 (Poloxamer 188, P188) as the standard shear protectant in sparged bioreactors. This reliance emerged from regulatory pressure to remove serum-derived contaminants, including BSE and TSE from manufacturing workflows. More recently, however, manufacturing disruptions linked to poloxamer 188, have …

InVitria and Cellevate Partner on Vaccine Manufacturing

InVitria has entered a strategic collaboration with Cellevate AB to explore improved upstream solutions for viral vaccine production. The collaboration brings together Cellevate’s Cellevat3d® nanofiber microcarrier platform with InVitria’s chemically defined recombinant proteins to support scalable, animal-origin-free vaccine manufacturing workflows. Cellevat3d enables high-density adherent cell culture, while InVitria’s recombinant media components help provide consistent and …

Enhancing Cell Therapy Consistency and Safety

This poster evaluates recombinant human serum albumin (rHSA, Optibumin® 25) as a structurally defined alternative to plasma-derived human serum albumin (pHSA) in T cell wash and cryopreservation workflows. Analytical characterization (SEC and Cys34 redox) demonstrates reduced aggregate burden and structural heterogeneity, with functional validation in T cell and MSC cryopreservation, including reduced-DMSO conditions. Equivalent T …

InVitria Product Catalog

The InVitria 2026 Product Catalog provides a comprehensive overview of recombinant, animal-origin-free proteins and chemically defined solutions designed for modern biomanufacturing. These products support a wide range of applications including cell and gene therapy manufacturing, biologics production, vaccine development, regenerative medicine, and diagnostics. Inside the catalog, you will find detailed information on InVitria’s portfolio of …

Replacing the “Necessary Evil”: Recombinant Human Serum Albumin as a Chemically Stable Alternative to Polysorbates in Biopharmaceutical Formulation

Reading time: 4 minutes Share this article: Polysorbate 20 and polysorbate 80 have long been treated as default stabilizers in biopharmaceutical formulations. They are effective surfactants and, for many years, have been viewed as a practical solution to interfacial stress and aggregation. Over time, however, a growing body of evidence has shown that these excipients …

The “Cheap” Albumin Paradox: The Actuarial Cost of Serum Albumin in Biomanufacturing

Reading time: 7 minutes Share this article: For decades, in the procurement ledgers of biopharmaceutical manufacturing, serum-derived Human Serum Albumin (HSA) often appears as a commodity staple. It is treated as a cost-effective stabilizer, typically priced in the market at approximately $5-$10 per gram. This price point, established by decades of plasma fractionation infrastructure, creates …

High-Resolution Analytical Characterization of Optibumin®: Structural Homogeneity and Functional Consistency Compared to Plasma-Derived HSA

EXECUTIVE SUMMARY Raw material consistency is critical to reproducible biopharmaceutical manufacturing and cell culture performance. Human serum albumin (HSA) is widely used as a functional excipient, yet plasma-derived HSA (pHSA) exhibits structural heterogeneity and lot-to-lot variability that can affect downstream applications. Structural homogeneity directly influences ligand binding and conjugation performance. This application note presents a …

Supply Chain Resilience: The Fragility and Finite Nature of Serum-Derived Raw Materials

Reading time: 7 minutes Share this article: The biopharmaceutical supply chain is currently resting on a fragile foundation of animal- and human-derived raw materials. As the number of approved biologics and advanced therapies continues to grow, demand for serum-derived components is increasing against a finite and increasingly constrained supply base. This article examines four primary …

Safety and Contamination Risks: The Testing Burden and Persistent Threats

Reading time: 3 minutes Share this article: Biomanufacturing safety is currently compromised by the persistent risk of adventitious agents inherent to serum-derived products. Fetal bovine serum (FBS) is frequently contaminated with bovine viral diarrhea virus (BVDV), a virus that can evade standard filtration and survive irradiation. Human AB serum presents a different but equally significant …